TransCelerate BioPharma Inc.: TransCelerate BioPharma to Highlight Collaboration, Innovation, and Patient-Centric Research at DIA 2025

TransCelerate BioPharma (TransCelerate), a nonprofit organization dedicated to improving the health of people around the world by accelerating and simplifying the clinical research process, today announced its participation in numerous sessions at the DIA 2025 Global Annual Meeting in Washington, D.C. from June 15–19.

King & Spalding: Administrative, Congressional, and State Interest Signal a Potential Breakthrough Moment for Psychedelics

In 2024, a workshop cohosted by FDA and the Reagan-Udall Foundation for the FDA (Reagan-Udall) focusing on advancing psychedelic clinical study design. Also in 2024, a second workshop by Reagan-Udall focusing specifically on understanding potential therapeutic uses of ketamine.